As a National Clinic Trials Network Lead Academic Participating Site, we hope to accomplish the following: 1. To provide scientific leadership and intellectual input in the creation of thoughtful, feasible trials to improve the health of cancer patients. We will accomplish this aim through the ongoing participation in clinical trials that spn the spectrum of disease-specific and radiation and surgical oncology;by applying the UNC culture of multidisciplinary care to make NCTN trials stronger and more modern;by leveraging the commitment of junior faculty, who will be the leaders of tomorrow; and by applying health services research in the development of clinical trials, including factors important to clinical outcomes, such as cost effectiveness, delivery of care, and policy. 2. To continue to be strong supporters of Network trials, through our rapidly growing clinical enterprise and robust accrual. We will support this aim by building on our historically strong accrual to CALGB, GOG, and ACOSOG trials and our well-funded and organized infrastructure, and through active participation across the NCTN. 3. To provide opportunities for excellent translational science embedded in NCTN clinical trials. UNC has a long commitment to translational science and has served as reference lab across multiple trials, with substantial (more than $3 million) investment in Next Generation sequencing and genomics;we are well suited to serve as a translational research collaborator for clinical trials in the future.
The UNC Lineberger Lead Academic Participating Site brings together an accomplished group of academic clinical oncologists and faculty from related disciplines, organized into multidisciplinary disease-site groups, to undertake cutting edge clinical research across the spectrum of cancers. The UNC LAPS will commit the staff and professional resources to manage and evaluate these research activities, accrue patients, and share knowledge with the wider research community. This effort will serve to enhance the understanding of cancer progression and treatment, lead to new studies based on information learned, and improve outcomes for patients.
|Ollila, David W; Cirrincione, Constance T; Berry, Donald A et al. (2017) Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). J Am Coll Surg 224:688-694|
|Wang, Xiaofei; Wang, Xiaoyi; Hodgson, Lydia et al. (2017) Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist 22:189-198|
|Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398|
|Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050|
|Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442|
|Perez, Edith A; Ballman, Karla V; Mashadi-Hossein, Afshin et al. (2017) Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. J Natl Cancer Inst 109:|
|Fuchs, Charles S; Niedzwiecki, Donna; Mamon, Harvey J et al. (2017) Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol 35:3671-3677|
|Shapiro, Charles L; Moriarty, James P; Dusetzina, Stacie et al. (2017) Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). J Clin Oncol 35:3949-3955|
|Smith, Sonali M; Pitcher, Brandelyn N; Jung, Sin-Ho et al. (2017) Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol 4:e176-e182|
|Freedman, Rachel A; Seisler, D K; Foster, J C et al. (2017) Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat 161:363-373|
Showing the most recent 10 out of 73 publications